Complement C1 Inhibitor Protein
"Complement C1 Inhibitor Protein" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An endogenous 105-kDa plasma glycoprotein produced primarily by the LIVER and MONOCYTES. It inhibits a broad spectrum of proteases, including the COMPLEMENT C1R and the COMPLEMENT C1S proteases of the CLASSICAL COMPLEMENT PATHWAY, and the MANNOSE-BINDING PROTEIN-ASSOCIATED SERINE PROTEASES. C1-INH-deficient individuals suffer from HEREDITARY ANGIOEDEMA TYPES I AND II.
| Descriptor ID |
D050718
|
| MeSH Number(s) |
D12.644.861.140.500 D12.776.124.486.274.920.250.500 D12.776.395.320 D12.776.872.140.500
|
| Concept/Terms |
Complement C1 Inhibitor Protein- Complement C1 Inhibitor Protein
- Serpin Family G Member 1
- C1 Esterase Inhibitor
- Esterase Inhibitor, C1
- C1-Inhibitor Protein
- C1 Inhibitor Protein
- Serpin G1
- G1, Serpin
- Plasma Protease C1 Inhibitor
- Complement C1-Inhibitor Protein
- SERPING1
- C1-INH Protein
- C1 INH Protein
|
Below are MeSH descriptors whose meaning is more general than "Complement C1 Inhibitor Protein".
Below are MeSH descriptors whose meaning is more specific than "Complement C1 Inhibitor Protein".
This graph shows the total number of publications written about "Complement C1 Inhibitor Protein" by people in this website by year, and whether "Complement C1 Inhibitor Protein" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2017 | 5 | 1 | 6 |
| 2018 | 1 | 2 | 3 |
| 2019 | 1 | 1 | 2 |
| 2020 | 1 | 1 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "Complement C1 Inhibitor Protein" by people in Profiles.
-
C1-Inhibitor: Structure, Functional Diversity and Therapeutic Development. Curr Med Chem. 2022; 29(3):467-488.
-
Impact of anxiety, stress and depression related to COVID-19 pandemic on the course of hereditary angioedema with C1-inhibitor deficiency. Allergy. 2021 08; 76(8):2535-2543.
-
Molecular Basis for Bordetella pertussis Interference with Complement, Coagulation, Fibrinolytic, and Contact Activation Systems: the Cryo-EM Structure of the Vag8-C1 Inhibitor Complex. mBio. 2021 03 23; 12(2).
-
Gene variants of coagulation related proteins that interact with SARS-CoV-2. PLoS Comput Biol. 2021 03; 17(3):e1008805.
-
Safety and Outcomes Associated with the Pharmacological Inhibition of the Kinin-Kallikrein System in Severe COVID-19. Viruses. 2021 02 16; 13(2).
-
C1 Esterase Inhibition: Targeting Multiple Systems in COVID-19. J Clin Immunol. 2021 05; 41(4):729-732.
-
Evaluation of the efficacy and safety of icatibant and C1 esterase/kallikrein inhibitor in severe COVID-19: study protocol for a three-armed randomized controlled trial. Trials. 2021 Jan 20; 22(1):71.
-
Recombinant human C1 esterase inhibitor (conestat alfa) in the prevention of severe SARS-CoV-2 infection in hospitalized patients with COVID-19: A structured summary of a study protocol for a randomized, parallel-group, open-label, multi-center pilot trial (PROTECT-COVID-19). Trials. 2021 Jan 04; 22(1):1.
-
Age-dependent possible role of contact-activated blood coagulation factor XII as a potential contributor to the “bradykinin storm” in COVID-19 patients Orv Hetil. 2020 12 13; 161(50):2099-2103.
-
Treatment of COVID-19 With Conestat Alfa, a Regulator of the Complement, Contact Activation and Kallikrein-Kinin System. Front Immunol. 2020; 11:2072.